CA3246896A1 - COMPOSITIONS AND METHODS FOR THE DETECTION OF LUNG CANCER - Google Patents

COMPOSITIONS AND METHODS FOR THE DETECTION OF LUNG CANCER

Info

Publication number
CA3246896A1
CA3246896A1 CA3246896A CA3246896A CA3246896A1 CA 3246896 A1 CA3246896 A1 CA 3246896A1 CA 3246896 A CA3246896 A CA 3246896A CA 3246896 A CA3246896 A CA 3246896A CA 3246896 A1 CA3246896 A1 CA 3246896A1
Authority
CA
Canada
Prior art keywords
biomarker
antigen
target
detection
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246896A
Other languages
English (en)
French (fr)
Inventor
Joseph Charles Sedlak
Laura Teresa Bortolin
Daniel Parker Salem
Emily Susan Winn-Deen
Daniel Gusenleitner
Anthony David Couvillon
Kelly Biette
Ibukunoluwapo O. Zabroski
Original Assignee
Mercy Bioanalytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercy Bioanalytics Inc filed Critical Mercy Bioanalytics Inc
Publication of CA3246896A1 publication Critical patent/CA3246896A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3246896A 2022-01-07 2023-01-06 COMPOSITIONS AND METHODS FOR THE DETECTION OF LUNG CANCER Pending CA3246896A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263297684P 2022-01-07 2022-01-07
US63/297,684 2022-01-07
US202263417299P 2022-10-18 2022-10-18
US63/417,299 2022-10-18
PCT/US2023/010358 WO2023133299A1 (en) 2022-01-07 2023-01-06 Compositions and methods for detection of lung cancer

Publications (1)

Publication Number Publication Date
CA3246896A1 true CA3246896A1 (en) 2023-07-13

Family

ID=87074171

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246896A Pending CA3246896A1 (en) 2022-01-07 2023-01-06 COMPOSITIONS AND METHODS FOR THE DETECTION OF LUNG CANCER

Country Status (5)

Country Link
US (1) US20250223649A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460697A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025504786A (cg-RX-API-DMAC7.html)
CA (1) CA3246896A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023133299A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116904521B (zh) * 2023-09-13 2024-01-26 四川大学华西医院 一种突变型肺腺癌细胞系、构建方法和应用
CN117568353B (zh) * 2023-10-20 2025-09-30 中国科学院基础医学与肿瘤研究所(筹) 一种核酸适体的活体筛选方法及筛选获得的核酸适体
CN120102887B (zh) * 2025-05-10 2025-07-25 浙江格物致知生物科技有限公司 一种检测肺癌的联检产品及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
WO2012024543A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
CN103874770A (zh) * 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
DK3321355T3 (da) * 2011-12-30 2021-11-08 Amit Patel Fremgangsmåder og sammensætninger til klinisk afledning af en allogen celle og terapeutiske anvendelser
CN111971560B (zh) * 2017-12-01 2024-06-11 康奈尔大学 用于检测和治疗癌症的纳米颗粒和不同的外泌体子集
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
KR20230044429A (ko) * 2020-07-08 2023-04-04 메르시 바이오애널리틱스, 인코포레이티드 폐암의 검출을 위한 조성물 및 방법

Also Published As

Publication number Publication date
EP4460697A1 (en) 2024-11-13
US20250223649A1 (en) 2025-07-10
WO2023133299A1 (en) 2023-07-13
JP2025504786A (ja) 2025-02-19
EP4460697A4 (en) 2026-06-24

Similar Documents

Publication Publication Date Title
US20240011993A1 (en) Compositions and methods for detection of lung cancer
US20240368701A1 (en) Compositions and methods for cancer detection
JP7344973B2 (ja) 標的実体を検出するためのシステム、組成物、及び方法
US20250223649A1 (en) Compositions and methods for detection of lung cancer
US20230243834A1 (en) Compositions and methods for detection of ovarian cancer
US20250297317A1 (en) Compositions and methods for detection of liver cancer
WO2023004083A2 (en) Compositions and methods for detection of bile duct cancer
US20250043357A1 (en) Compositions and methods for detection of esophageal cancer
US20240377401A1 (en) Compositions and methods for detection of prostate cancer
US20240369558A1 (en) Compositions and methods for detection of breast cancer
US20240344139A1 (en) Compositions and methods for detection of colorectal cancer
US20240369560A1 (en) Compositions and methods for detection of pancreatic cancer
JP2024543085A (ja) 卵巣がんの検出のための組成物および方法
HK40007814A (en) Oligonucleotide probes and uses thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240704

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241212

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241212

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241212

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251118